AKIN GUMP STRAUSS HAUER & FELD

Lobbying for KYVERNA THERAPEUTICS, INC. · Biopharmaceutical company focused on developing cell therapies for autoimmune diseases.

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

California

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 1

Health Issues

Issues related to developing cell therapies for patients, including Stiff Person Syndrome, rare disease, and multiple sclerosis.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.